Glass half full. The phase 3 trial will be starting shortly. (before end of year) Both Acadia and Neuren will be conducting and monitoring. If successful it should start to be evident within weeks. Very low bar FDA has set to just replicate Phase 2! Talk of then waiting 13 months for FDA to officially approve would imo be unnecessary. Both Acadia and Neuren would look at what is before them and work on that. Also anyone that Torreya bring in from ROW will help Neu in bidding war. Not long to wait!
Goldman Sachs Healthcare Conference, page-35
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |